Clinical Oncology

[Gastrointestinal cancers: role of biomarkers and based on driven treatment of gastrointestinal cancers]

PAJKOS Gábor1

NOVEMBER 30, 2021

Clinical Oncology - 2021;8(4)

[Remarkable advancements in techniques of genomic profiling and bioinformatics have led to the precision medicine in oncology approach, targeted therapy and immune checkpoint inhibitors achieved radically change in treatment efficacy based on accumulation of knowledge on the genomic profiles of gastrointestinal tract cancer (GI). Advanced or disseminated poor risk GI cancer patients have had a better chance for that progression free and/or overall survival. Highly effective treatment needs to incorporate numerous molecular characteristic into clinics – expression of PD-L1, MSI (micro satellite instability)/dMMR (defective mismatch repair), TMB (tumor mutation burden), resistance mutation, insertions/deletions and other genomic alterations. This review aims to summarize predictive and prognostic biomarkers might suggested for precision oncology treatment of GI cancers.]

AFFILIATIONS

  1. Szegedi Tudományegyetem, Szent-Györgyi Albert Orvostudományi Kar Oktató Kórháza, Kecskemét, Onkoradiológiai Központ

COMMENTS

0 comments

Further articles in this publication

Clinical Oncology

[New systemic treatment possibilities in non-small cell lung cancer]

OSTOROS Gyula, BOGOS Krisztina

Clinical Oncology

[Microbiome and cancer]

MIKÓ Edit, BAI Péter

[Most compartments and organs of the human body are not sterile, bacterial DNA and RNA can be detected using next generation sequencing techniques. All bacterial DNA in a compartment is called the metagenome, all bacterial transcripts are termed metatranscriptome, while all bacterial species is coined the microbiome. The microbiome transforms in neoplastic diseases that is called the oncobiome. Most tumors are colonized by bacteria that supports tumor growth and development. Microbiome compartments distant to the tumors (as the microbiome of the gastrointestinal tract) can also undergo oncobiotic transformation. The metabolic capacity of the oncobiotic microbiome in the gastrointestinal tract is suppressed and the production of a large set of cytostatic and antimetastatic bacterial metabolites is blunted supporting cancer cells proliferation and metastasis. The microbiome of the gastrointestinal tract has pivotal role in setting the tolerance of the immune system against cancer cells, therefore, has prime importance in tumor immunity. Oncobiosis, by itself, cannot induce tumors, but can support tumor growth and metastasis formation. Bacteria have key role in the success of cytostatic therapy and in setting the side effect profile.]

Clinical Oncology

[Pancreas cancer: Therapeutic trials in metastatic disease]

SMITHY W. James , O’REILLY M. Eileen

Clinical Oncology

[Mechanisms of metastasis formation as potential therapeutic targets]

TÍMÁR József, SEBESTYÉN Anna, KOPPER László

[The end-stage of the tumor progression is the development of the metastatic disease. The biological basis of this progression is well known, however the exact molecular background of it is not. In this process the metastatic cancer cells develop maximal adaptation to extreme environmental clues and collaborative potential with wide array of host cells, accordingly the metastatization takes place in an organ specific manner. The metastases are different from the primary tumor but from each other as well, and this true for their genetic background as well. The ultrasensitive monitoring of this process is possible with the use of liquid biopsy and molecular tests. Till we don’t have organ metastasis specific therapeutic modalities similarly to bone metastases, the available modalities must be fine-tuned for metastatic disease and not for the primary tumor. ]

Clinical Oncology

[The concept and use of placebo and nocebo in oncology]

VÉGH Éva, BAKI Márta

[Placebo and nocebo effects recognised through all of the history of medicine, and these effects can be found also in the field of oncology research and clinical practice. Placebo effect are more than the effects of an inert substance. Placebo benefits the health status because of the person’s belief and nocebo worsens the health status of the patient. Several psychological mechanisms are involved in placebo/nocebo effects; expectation, learning processes (classical conditioning and observational learning), reinforced expectations, personality traits of the patient and the health care provider. At the same time placebo effects rely on neurobiologic mechanism (neurotransmitters like dopamine, cholecystokinin, opioids and activation of specific brain areas). The use of placebo is an important methodological tool in oncological research and drug development. Inert substance can be associated with positive (placebo) and negative (nocebo) adverse event profiles also can modify the measured therapeutic effects in randomized clinical trials.]

All articles in the issue

Related contents

Clinical Neuroscience

[Controversies in neurology: Diagnosis, follow up and therapy of multiple sclerosis with pathomechanismal approach]

VÉCSEI László

[The clinical boundaries between the relapsing and progressive course of multiple sclerosis are often indistinct. Despite the variable patterns of evolution, there are no biological reasons for discerning different multiple sclerosis phenotypes. Indeed, both primary progressive and secondary forms of the disease share similar pathological features in respect of the extent of inflammatory infiltrates, axonal damage, and cortical demyelination. The data indicating that primary progressive multiple sclerosis is preceded by an asymptomatic relapsing remitting phase. The proposed definition of secondary progressive multiple slcerosis, the attainment of at least EDSS of 4 is required to mark the transition to the progressive phase. Therefore, the clinical progress can be uncovered in the early phase of the disease. Furthermore, a continuous progression independent of relapsing activity is commonly observed during the relapsing remitting phase. A continuous smouldering process underpins the subtle clinical deterioration, which stands out as an important unmet treatment target. Concerning cognitive dysfunction of the patients pro-inflammatory cytokines have been associated with worse cognition in active multiple sclerosis, and this inflammatory milieu could also contribute to altered mentation during relapses. Therefore, long before people with multiple sclerosis become physically disabled, they have usually acquired hidden disabilities related to cognitive impairment. Silent progression appears during the relapsing remitting phase and it associates with brain atrophy. This suggests that the same process that underlies secondary progressive multiple sclerosis likely begins far earlier than is generally recognized. This supports a unitary view of multiple sclerosis biology. ]

Clinical Neuroscience

[Current questions of multiple sclerosis: the secunder progressive form of the disease]

VÉCSEI László

[Recent data suggest that long-term worsening is common in relapsing-remitting multiple sclerosis patients and is largely independent of relapses or new lesion formation on brain MRI. The current definition of secunder progressive multiple sclerosis is worsening of disability independent of relapses over at least 6-month interval. Early focal inflammatory disease activity and spinal cord lesion are predictors of very-long term disease outcomes in relapse - onset multiple sclerosis. The potential of PET imaging to visualize hidden inflammation in MS brain in vivo is an important contribution for better understanding the progression of the disease. Therefore, PET imaging is a promising tool in detecting the conversion from relapsing remitting multiple sclerosis to secunder progressive form of multiple sclerosis. Furthermore, neuro-axonal damage is the pathological substrate of permanent disability in different neurological disorders including multiple sclerosis. The neurofilament proteins have promise in this context because their levels rise upon neuro-axonal damage not only in the cerebrospinal fluid but also in blood. Patients with increased serum levels of neurofilament at baseline, independent of other clinical and MRI variables, experience significantly more brain and spinal cord volume loss over 2 years and 5 years of follow-up. The kynurenine-pathway abnormalities may be associated with the swich from early-mild stage multiple sclerosis to debilitating progressive forms of the disease. Analysis of these metabolites in serum may have application as multiple sclerosis disease biomarkers. Free radical action has been suggested as a causal factor in the illness. Increased free radical production and consumption of the scavenger molecules were found during the active phase of the disease. Based on the clinical findings (EXPAND Study) and pathomechanism of the disease siponimod is approved by the US Food and Drug Administration for the treatment of relapsing remitting forms of multiple sclerosis, to include secunder progressive multiple sclerosis with active disease, relapsing-remitting multiple sclerosis and clinically isolated syndrome.]

Clinical Neuroscience

Additional value of tau protein measurement in the diagnosis of Creutzfeldt-Jakob disease

CSEH Katalin Edina, VERES Gábor, DANICS Krisztina, SZALÁRDY Levente, NÁNÁSI Nikolett, KLIVÉNYI Péter, VÉCSEI László, ZÁDORI Dénes

Since the definite diagnosis of Creutzfeldt-Jakob disease (CJD) can currently only be provided by autopsy, there is a special need for fine diagnostic tools in live patients to achieve accurate diagnosis as early as possible. The aim of this study was to perform a preliminary retrospective analysis on the utility of the measurement of total Tau (tTau) and some other biomarkers from the cerebrospinal fluid (CSF) of patients with rapidly progressive dementia in the diagnostic work up of CJD. Beside the assessment of relevant clinical data and the findings of electroencephalography and brain magnetic resonance imaging, the presence of 14-3-3 protein and the levels of tTau were determined by Western blot technique and enzyme-linked immunosorbent assay from the CSF of 19 patients diagnosed with rapidly progressive dementia between the period of 2004-2017 at the Department of Neurology, University of Szeged. This preliminary study provided 100% sensitivity for 14-3-3, and interestingly, only 40% specificity to support the clinical diagnosis of CJD. Regarding tTau, the sensitivity values were calculated to be 100% or 83%, whereas the specificity values were 71% or 86%, depending on the applied cut-off levels. The poor specificity of 14-3-3 is not in line with literature data and may be the result of the small number of patients in the cohort with non-prion disease, predominantly consisting of disorders with considerable tissue damage, whereas tTau presented good sensitivity and specificity values. The combined application of these and novel chemical biomarkers may increase both sensitivity and specificity to a desired level.

Clinical Oncology

[Radiological response evaluation of targeted therapy]

KALINA Ildikó, OSZLÁNSZKY György

[The objective assessment of the changes in the tumor burden along with cancer therapy has essential importance. Recently, the quantitative evaluation of the radiological tumor response was undergone several changes. For conventional chemotherapy of solid tumors the standard procedure has been RECIST since 2000. The targeted therapies trigger other pathophysiological changes in the cells than the cytotoxic agents, accordingly the morphological changes show a new picture. Therefore the targeted therapies require a new evaluation system, that takes into consideration not only the tumor size, but other changes as well, the changes of attenuation that corresponds with the proportion of the viable cells. In case of the targeted therapies in substantial clinical was experienced even without signifi cant morphological changes in the tumour size. As a consequence, the traditional, size-based criteria system can underestimate the effi ciency of the new types of treatments. To eliminate this problem new evaluation systems were created taking the tumortypes and treatment protocolls into consideration. The estimation of the early tumor response to targeted therapy also has high importance. In assessment of the response functional imaging methods are used more frequently. The role of PET has already been defi ned in numerous tumortypes, however the determination of the position of some promising functional examinations still require further studies.]

Clinical Oncology

[Treatment of hepatocellular carcinoma - today]

VÉGH Éva, DEMETER Gyula, BODOKY György

[The hepatocellular carcinoma (HCC) is one of the main causes of cancer-related death globally, and at the same time, it is the main event leading to death in cirrhotic patients. In the etiology of HCC, the non-alcoholic liver disease may be an important cause besides the viral cirrhosis. The HCC’s staging systems (Child-Pugh scores, Cancer of the Liver Italian Programme/CLIP, Barcelona Clinic Liver Cancer/ BCLC) play an important role in predicting the prognosis and determining the appropriate therapy. In Europe, the treatment strategy is based on the BCLC staging system. Screening of cirrhotic patient is also important because curative therapy is available only for the early-stage HCC. Several therapeutic options exist in the intermediate stage disease; among them the radiofrequency ablation (RFA), the transarterial chemoembolization (TACE) and the percutan ethanol injection (PEI) are most important. For the advanced disease, the only approved systemic therapy is sorafenib, which has been well-tolerated and yielded a substantially relative improvement in overall survival. For patient in end-stage disease with impaired liver function or a poor performance status, only supportive care is recommended.]